While the number of NME approvals are not as high as they were at this time last year, “it is actually not far behind 2015, which was a record-setter by the end of the year, indicating that a midyear assessment is not always a very crystal ball regarding the rest of the year,” Eye on the FDA reported.
Some indicators that suggest 2019 may not be a record-setting year, according to the blog. There are fewer advisory panel meetings to decide on new drug approvals in 2019 and fewer deadlines for agency approvals this year compared to last year.
Read the full blog post here.
More articles on pharmacy:
Judge blocks HHS rule requiring drug prices in TV ads
Nation’s 1st prescription drug affordability board goes into effect
11 healthcare pharma leaders offer advice on controlling drug spend
